Abbott Laboratories (NYSE:ABT) had its price target upped by Jefferies Group from $44.00 to $46.00 in a research note issued to investors on Monday, AnalystRatingsNetwork reports. The firm currently has a buy rating on the stock.
Shares of Abbott Laboratories (NYSE:ABT) traded up 0.57% on Monday, hitting $37.23. 7,571,098 shares of the company’s stock traded hands. Abbott Laboratories has a 52-week low of $30.0451 and a 52-week high of $38.77. The stock’s 50-day moving average is $35.06 and its 200-day moving average is $35.7. The company has a market cap of $57.860 billion and a P/E ratio of 19.59.
Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Wednesday, October 16th. The company reported $0.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.52 by $0.03. The company had revenue of $5.37 billion for the quarter, compared to the consensus estimate of $5.46 billion. During the same quarter in the previous year, the company posted $1.30 earnings per share. The company’s revenue for the quarter was up 2.0% on a year-over-year basis. On average, analysts predict that Abbott Laboratories will post $2.02 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which is scheduled for Saturday, February 15th. Stockholders of record on Wednesday, January 15th will be paid a dividend of $0.22 per share. This represents a $0.88 annualized dividend and a dividend yield of 2.36%. The ex-dividend date is Monday, January 13th. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.14.
Other equities research analysts have also recently issued reports about the stock. Analysts at Zacks reiterated a neutral rating on shares of Abbott Laboratories in a research note to investors on Thursday, October 17th. They now have a $38.00 price target on the stock. Separately, analysts at Stifel Nicolaus cut their price target on shares of Abbott Laboratories from $44.00 to $40.00 in a research note to investors on Monday, October 7th. They now have a buy rating on the stock. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and ten have assigned a buy rating to the stock. The stock has a consensus rating of Hold and a consensus target price of $38.21.
Abbott Laboratories (NYSE:ABT), is engaged in the discovery, development, manufacture, and sale of a portfolio of science-based health care products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.